基于非病毒基因载体的肿瘤免疫联合治疗研究进展  

Advances in tumor combined-immunotherapy based on non-viral gene vectors

作　　者：杨成莉 李明 郑志昌 YANG Chengli;LI Ming;ZHENG Zhichang(Department of Pharmacy,the Affiliated Hospital of Guizhou Medical University,Guizhou Guiyang 550000,China.)

机构地区：[1]贵州医科大学附属医院药剂科,贵州贵阳550000

出　　处：《现代肿瘤医学》2023年第8期1550-1554,共5页Journal of Modern Oncology

基　　金：国家自然科学基金地区基金(编号:81860543);贵州省中医药管理局中医药、民族医药科学技术研究课题(编号:QZYY-2016-017)。

摘　　要：据全球癌症数据统计,2020年新发癌症病例1929万例,我国肿瘤发病率占全世界23.7%,寻找治疗肿瘤有效手段迫在眉睫,而基于基因的免疫治疗在癌症方面具有巨大潜力。本文总结近年来基于纳米递送系统的基因免疫治疗在癌症免疫及免疫联合治疗中应用的种类及发展情况,这其中包括mRNA、DNA和基因编辑疗法等。通过该综述研究,有望对基于非病毒基因载体的肿瘤免疫联合治疗领域有更深刻的了解,为临床前基础研究提供依据。According to global cancer statistics,there were 19.29 million new cancer cases in 2020,the incidence of cancer in China accounted for 23.7%of the world.Thus,the search for an effective treatment for cancer is urgent,and gene-based immunotherapy for cancer has great potential.In this paper,the main types and development of gene immunotherapy based on nano-delivery system,including mRNA,DNA and genome editing therapy,in cancer immunotherapy and immunocombination therapy,were summarized.Through this review,it is expected to have a deeper understanding of the field of tumor immunotherapy based on non-viral gene vectors.

关 键 词：非病毒载体 基因 免疫治疗 联合治疗 

分 类 号：R730.5[医药卫生—肿瘤]